EV/EBITDA spoločnosti Inhibrx
Aká je hodnota metriky EV/EBITDA spoločnosti Inhibrx?
Hodnota metriky EV/EBITDA spoločnosti Inhibrx, Inc. je N/A
Aká je definícia metriky EV/EBITDA?
EV/EBITDA je podniková hodnota vydelená EBITDA (zisk pred odpočítaním úrokov, daní, odpisov, a amortizácie). Meria nákladnosť akcie a používa sa na porovnávanie spoločností medzi sebou častejšie ako P/E ratio. Meria cenu akú investor zaplatí za pohyb hotovosti v spoločnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Inhibrx
Čomu sa venuje spoločnosť Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Firmy s metrikou ev/ebitda podobnou spoločnosti Inhibrx
- Hodnota metriky EV/EBITDA spoločnosti Wishpond Technologies je N/A
- Hodnota metriky EV/EBITDA spoločnosti Future Bright je N/A
- Hodnota metriky EV/EBITDA spoločnosti GoldQuest Mining je N/A
- Hodnota metriky EV/EBITDA spoločnosti Powercell Sweden Sk ,022 je N/A
- Hodnota metriky EV/EBITDA spoločnosti O3 Mining je N/A
- Hodnota metriky EV/EBITDA spoločnosti Tijaria Polypipes je N/A
- Hodnota metriky EV/EBITDA spoločnosti Inhibrx je N/A
- Hodnota metriky EV/EBITDA spoločnosti Kidsland International je N/A
- Hodnota metriky EV/EBITDA spoločnosti Americas Car Mart je N/A
- Hodnota metriky EV/EBITDA spoločnosti Reabold Resources Plc je N/A
- Hodnota metriky EV/EBITDA spoločnosti Ausmex Mining je N/A
- Hodnota metriky EV/EBITDA spoločnosti amalphi ag je N/A
- Hodnota metriky EV/EBITDA spoločnosti Silver Range Resources je N/A